Dr. Dietrich on Future Research Directions in Lung Cancer

Video

In Partnership With:

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer. 

Martin Dietrich, MD, PhD, assistant professor, University of Central Florida, fellow, American College of Physicians, Florida Cancer Specialists & Research Institute, discusses future research directions for the treatment of patients with lung cancer. 

A potentially practice-changing trial is the ongoing phase 3 LAURA study (NCT03521154), which is examining the efficacy and safety of osimertinib (Tagrisso) following chemoradiation in patients with stage III unresectable non­–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations, according to Dietrich. Based on data from the phase 3 PACIFIC trial (NCT02125461), it is clear that this subset of patients derives some benefit from additional treatment in this setting, Dietrich adds.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD